Blood filtering shows promise for severe COVID-19 patients

NCT ID NCT04751643

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether filtering the blood (therapeutic plasma exchange) could help severe COVID-19 patients by removing harmful immune molecules that cause lung damage. Twenty-one adults in intensive care with COVID-19 and lung failure were randomly assigned to receive either blood filtering plus standard care or standard care alone. The main goal was to see if the treatment reduced the need for a breathing tube.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
therapeutic plasma exchange (blood filtering)
What this could lead to
If it works, this could provide a way to quickly calm the immune overreaction in severe COVID-19, potentially reducing the need for breathing machines.
What could go wrong
This was a very small, early trial with only 21 participants, so results may not apply broadly. Plasma exchange also carries risks like allergic reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69310, France

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, 71100, France

  • Clinique de la Sauvegarde

    Lyon, 69337, France

  • Groupement Hospitalier Porte de Valence - Montélimar

    Montélimar, 26216, France

  • Hôpital Croix Rousse

    Lyon, 69004, France

  • Hôpital Edouard Herriot

    Lyon, 69003, France

  • Hôpital Pitié Salpétrière - Assistante Publique des Hôpitaux de Paris

    Paris, 75013, France

  • Medipole Villeurbanne

    Villeurbanne, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.